synthetic human papillomavirus 16 e6 peptide
Vaccineexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 1995 (NCT00019110)
Timeline
Indications
Mechanism of action
- Human papillomavirusImmunity, active
Human papillomavirus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- synthetic human papillomavirus 16 e6 peptide
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00002916 | Phase 2 | Nov 1, 1996 | European Organisation for Research and Treatment of Cancer, University of Dundee |
| NCT00019110 | Phase 1 | Nov 1, 1995 | National Cancer Institute (NCI) |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| European Organisation for Research and Treatment of Cancer | Academic/Hospital | 1 | 1 | 1 | 1996 |
| National Cancer Institute (NCI) | Government | 1 | 1 | 1 | 1995 |
| University of Dundee | Academic/Hospital | 1 | 0 | 1 | 1996 |
3 organizations
Page 1 / 1